{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T08:24:50Z","timestamp":1765355090948,"version":"3.40.4"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFE0206300"],"award-info":[{"award-number":["2021YFE0206300"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82403969, No. 82073391, No. 81773279"],"award-info":[{"award-number":["No. 82403969, No. 82073391, No. 81773279"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Given the substantial inconvenience caused by weekly bleomycin administration, we initiated a study to evaluate the efficacy and toxicity of the modified bleomycin combined with EP (modified-BEP) regimen in Chinese adult male patients with germ cell tumors (GCTs).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We conducted a retrospective analysis of 274 adult male GCT patients treated with modified-BEP at the Sun Yat-sen University Cancer Center between 2005 and 2022. The regimen involved a tri-weekly 5-day schedule with 30 IU modified bleomycin (administered on days 1, 3, and 5), 20 mg\/m2 cisplatin (days 1\u20135), and 100 mg\/m2 etoposide (days 1\u20135). The survival rates and safety profiles of the patients were analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Among the patients, 42 patients received BEP in adjuvant setting, while 232 were treated with BEP in curative setting. With a median follow-up of 41.03 months among the curative patient population, the 5-year progression-free survival (PFS) rate was 79.33%, and the 5-year overall survival (OS) rate was 86.26%. Stratified by the International Germ Cell Cancer Collaborative Group (IGCCCG) prognostic groups, the 5-year OS rates of the good, intermediate, and poor risk groups were 99.05%, 92.84%, and 55.96% (P\u2009&lt;\u20090.0001), respectively. Favorable responses, including complete remission and partial response with negative tumor markers, were achieved in 91.07% of good-risk, 84.13% of intermediate-risk, and 52.63% of poor-risk patients, with a significant difference (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001). Multivariate analysis indicated that non-seminoma, poor risk group, mediastinal primary tumor, and Eastern Cooperative Oncology Group (ECOG) 2 status were significantly associated with inferior PFS. In the entire cohort, major grade 3\u20144 adverse events included neutropenia (38.69%), anemia (4.74%), thrombocytopenia (5.11%), and febrile neutropenia (6.2%), with no death due to pulmonary toxicity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The modified-BEP regimen showed an effective and tolerable treatment alternative for adult male GCT patients in China, offering greater convenience compared to the standard BEP regimen.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12935-025-03774-2","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T18:38:51Z","timestamp":1744828731000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of modified bleomycin administration with EP chemotherapy in adult male patients with germ cell tumors: a retrospective study"],"prefix":"10.1186","volume":"25","author":[{"given":"Ditian","family":"Shu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riqing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haifeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cong","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anqi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangjian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuowei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanxia","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"issue":"3","key":"3774_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"3774_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China 2015. CA Cancer J Clin. 2016;66(2):115\u201332.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"3774_CR3","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1200\/JCO.1997.15.2.594","volume":"15","author":"GM Mead","year":"1997","unstructured":"Mead GM, Stenning SP, Cook P, Fossa SD, Horwich A, Kaye SB, Oliver RT, et al. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol. 1997;15(2):594\u2013603.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3774_CR4","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1200\/JCO.1995.13.2.470","volume":"13","author":"PJ Loehrer Sr","year":"1995","unstructured":"Loehrer PJ Sr, Johnson D, Elson P, Einhorn LH, Trump D. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an eastern cooperative oncology group trial. J Clin Oncol. 1995;13(2):470\u20136.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3774_CR5","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1093\/annonc\/mdm062","volume":"18","author":"S Culine","year":"2007","unstructured":"Culine S, Kerbrat P, Kramar A, Th\u00e9odore C, Chevreau C, Geoffrois L, et al. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the genito-urinary group of the french federation of cancer centers (GETUG T93BP). Annals oncol. 2007;18(5):917\u201324.","journal-title":"Annals oncol"},{"issue":"6","key":"3774_CR6","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1097\/COC.0000000000000679","volume":"43","author":"G Aurilio","year":"2020","unstructured":"Aurilio G, Verri E, Frassoni S, Bagnardi V, Cossu Rocca M, Cullur\u00e0 D, et al. Modified-BEP chemotherapy in patients with germ-cell tumors treated at a comprehensive cancer center. Am J Clin Oncol. 2020;43(6):381\u20137.","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"3774_CR7","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/bjc.2011.309","volume":"105","author":"Y Rimmer","year":"2011","unstructured":"Rimmer Y, Chester J, Joffe J, Stark D, Shamash J, Powles T, et al. Accelerated BEP: a phase I trial of dose-dense BEP for intermediate and poor prognosis metastatic germ cell tumour. Br J Cancer. 2011;105(6):766\u201372.","journal-title":"Br J Cancer"},{"issue":"3","key":"3774_CR8","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.urology.2011.05.005","volume":"78","author":"A Tryakin","year":"2011","unstructured":"Tryakin A, Fedyanin M, Kanagavel D, Fainstein I, Sergeev J, Polockij B, et al. Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study. Urology. 2011;78(3):620\u20135.","journal-title":"Urology"},{"issue":"7","key":"3774_CR9","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1200\/JCO.2015.64.7909","volume":"34","author":"JJ Ko","year":"2016","unstructured":"Ko JJ, Bernard B, Tran B, Li H, Asif T, Stukalin I, et al. Conditional survival of patients with metastatic testicular germ cell tumors treated with first-line curative therapy. J Clin Oncol. 2016;34(7):714\u201320.","journal-title":"J Clin Oncol"},{"issue":"12","key":"3774_CR10","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S1470-2045(03)01279-8","volume":"4","author":"RH Jones","year":"2003","unstructured":"Jones RH, Vasey PA. Part II: testicular cancer\u2013management of advanced disease. Lancet Oncol. 2003;4(12):738\u201347.","journal-title":"Lancet Oncol"},{"issue":"14","key":"3774_CR11","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1200\/JCO.20.03296","volume":"39","author":"S Gillessen","year":"2021","unstructured":"Gillessen S, Sauv\u00e9 N, Collette L, Daugaard G, de Wit R, Albany C, et al. Predicting outcomes in men with metastatic nonseminomatous germ cell tumors (nsgct): results from the IGCCCG update consortium. J Clin Oncol. 2021;39(14):1563\u201374.","journal-title":"J Clin Oncol"},{"issue":"14","key":"3774_CR12","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1200\/JCO.20.03292","volume":"39","author":"J Beyer","year":"2021","unstructured":"Beyer J, Collette L, Sauv\u00e9 N, Daugaard G, Feldman DR, Tandstad T, et al. Survival and new prognosticators in metastatic seminoma: results from the IGCCCG-update consortium. J Clin Oncol. 2021;39(14):1553\u201362.","journal-title":"J Clin Oncol"},{"issue":"30","key":"3774_CR13","doi-asserted-by":"publisher","first-page":"3752","DOI":"10.1200\/JCO.2012.43.4431","volume":"30","author":"HS Haugnes","year":"2012","unstructured":"Haugnes HS, Bosl GJ, Boer H, Gietema JA, Bryd\u00f8y M, Oldenburg J, et al. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol. 2012;30(30):3752\u201363.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3774_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/annonc\/mdg020","volume":"14","author":"JM O'Sullivan","year":"2003","unstructured":"O\u2019Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Annal Oncol. 2003;14(1):91\u20136.","journal-title":"Annal Oncol"},{"issue":"6","key":"3774_CR15","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1093\/annonc\/mdx071","volume":"28","author":"J Shamash","year":"2017","unstructured":"Shamash J, Sarker SJ, Huddart R, Harland S, Joffe JK, Mazhar D, et al. A randomized phase III study of 72 h infusional versus bolus bleomycin in BEP (bleomycin, etoposide and cisplatin) chemotherapy to treat IGCCCG good prognosis metastatic germ cell tumours (TE-3). Ann Oncol. 2017;28(6):1333\u20138.","journal-title":"Ann Oncol"},{"issue":"3","key":"3774_CR16","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1200\/JCO.2007.13.8461","volume":"26","author":"S Culine","year":"2008","unstructured":"Culine S, Kramar A, Th\u00e9odore C, Geoffrois L, Chevreau C, Biron P, et al. Randomized trial comparing bleomycin\/etoposide\/cisplatin with alternating cisplatin\/cyclophosphamide\/doxorubicin and vinblastine\/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors genito-urinary group of the French federation of cancer centers trial T93MP. J Clin Oncol. 2008;26(3):421\u20137.","journal-title":"J Clin Oncol"},{"issue":"6","key":"3774_CR17","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1200\/JCO.2001.19.6.1629","volume":"19","author":"R de Wit","year":"2001","unstructured":"de Wit R, Roberts JT, Wilkinson PM, de Mulder PH, Mead GM, Foss\u00e5 SD, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European organization for research and treatment of cancer genitourinary tract cancer cooperative group and the medical research council. J Clin Oncol. 2001;19(6):1629\u201340.","journal-title":"J Clin Oncol"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-03774-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-025-03774-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-03774-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T18:38:52Z","timestamp":1744828732000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-025-03774-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3774"],"URL":"https:\/\/doi.org\/10.1186\/s12935-025-03774-2","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"21 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The clinical data were acquired with the approval and permission of the Institutional Review Board of the Sun Yat-sen University Cancer Center. The study protocol was approved by the ethical committee of Sun Yat-sen University Cancer Center (approval number B2022 -\u2009268\u00a0-\u00a001), and the study was performed according to the principles of the Declaration of Helsinki. Informed consent was not required because this study was a retrospective analysis of clinical data and posed no human biological ethical issues. Therefore, the need for informed consent was waived by the ethical committee of the Sun Yat-sen University Cancer Center. All methods were performed following relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"151"}}